source
- Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOAttovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for b…Fierce Biotech · 1d ago↗ source
- Vertex posts strong Q2 earnings, but upcoming Sionna cystic fibrosis data casts a shadowVertex reported Q2 revenue from its cystic fibrosis portfolio exceeding $3.2 billion, beating estimates and prompting an upward revision of full‑year revenue guidance to $13.1‑$13.2 billion. Analy…